These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31113806)

  • 1. An Artificial Antigen-Presenting Cell Delivering 11 Immune Molecules Expands Tumor Antigen-Specific CTLs in
    Zhang L; Song S; Jin X; Wan X; Shahzad KA; Pei W; Zhao C; Shen C
    Cancer Immunol Res; 2019 Jul; 7(7):1188-1201. PubMed ID: 31113806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEGylated and CD47-conjugated nanoellipsoidal artificial antigen-presenting cells minimize phagocytosis and augment anti-tumor T-cell responses.
    Song S; Jin X; Zhang L; Zhao C; Ding Y; Ang Q; Khaidav O; Shen C
    Int J Nanomedicine; 2019; 14():2465-2483. PubMed ID: 31040669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paracrine release of IL-2 and anti-CTLA-4 enhances the ability of artificial polymer antigen-presenting cells to expand antigen-specific T cells and inhibit tumor growth in a mouse model.
    Zhang L; Wang L; Shahzad KA; Xu T; Wan X; Pei W; Shen C
    Cancer Immunol Immunother; 2017 Sep; 66(9):1229-1241. PubMed ID: 28501941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial antigen-presenting cells plus IL-15 and IL-21 efficiently induce melanoma-specific cytotoxic CD8+ CD28+ T lymphocyte responses.
    Yu X; He J; Mongkhoune S; Peng Y; Xie Y; Su J; Zhou SF; Xie XX; Luo GR; Fang Y; Li X; Li X; Zhou N; Zhao YX; Lu XL
    Asian Pac J Trop Med; 2013 Jun; 6(6):467-72. PubMed ID: 23711708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response.
    Lu X; Jiang X; Liu R; Zhao H; Liang Z
    Cancer Lett; 2008 Nov; 271(1):129-39. PubMed ID: 18621475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer.
    Ugel S; Zoso A; De Santo C; Li Y; Marigo I; Zanovello P; Scarselli E; Cipriani B; Oelke M; Schneck JP; Bronte V
    Cancer Res; 2009 Dec; 69(24):9376-84. PubMed ID: 19934317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
    Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
    J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
    Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    Sutmuller RP; van Duivenvoorde LM; van Elsas A; Schumacher TN; Wildenberg ME; Allison JP; Toes RE; Offringa R; Melief CJ
    J Exp Med; 2001 Sep; 194(6):823-32. PubMed ID: 11560997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation.
    Li SY; Liu Y; Xu CF; Shen S; Sun R; Du XJ; Xia JX; Zhu YH; Wang J
    J Control Release; 2016 Jun; 231():17-28. PubMed ID: 26829099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of sulfosuccinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate conjugated GP100(25-33) peptide-coupled spleen cells effectively mounts antigen-specific immune response against mouse melanoma.
    Chang X; Xia CQ
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):46-52. PubMed ID: 26545782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Tolerogenic Artificial APC Durably Ameliorates Experimental Autoimmune Encephalomyelitis by Directly and Selectively Modulating Myelin Peptide-Autoreactive CD4
    Wan X; Pei W; Shahzad KA; Zhang L; Song S; Jin X; Wang L; Zhao C; Shen C
    J Immunol; 2018 Aug; 201(4):1194-1210. PubMed ID: 29987163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes.
    Sun L; Guo H; Jiang R; Lu L; Liu T; Zhang Z; He X
    Oncotarget; 2016 Apr; 7(14):17579-90. PubMed ID: 27007051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction.
    Schilbach K; Kerst G; Walter S; Eyrich M; Wernet D; Handgretinger R; Xie W; Rammensee HG; Müller I; Bühring HJ; Niethammer D
    Blood; 2005 Jul; 106(1):144-9. PubMed ID: 15731181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells.
    Ichikawa J; Yoshida T; Isser A; Laino AS; Vassallo M; Woods D; Kim S; Oelke M; Jones K; Schneck JP; Weber JS
    Clin Cancer Res; 2020 Jul; 26(13):3384-3396. PubMed ID: 32241816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-presenting T cells induce the development of cytotoxic CD4+ T cells. I. Involvement of the CD80-CD28 adhesion molecules.
    Mauri D; Wyss-Coray T; Gallati H; Pichler WJ
    J Immunol; 1995 Jul; 155(1):118-27. PubMed ID: 7541409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.